These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 28448462)

  • 1. Targeting the ATR-CHK1 Axis in Cancer Therapy.
    Rundle S; Bradbury A; Drew Y; Curtin NJ
    Cancers (Basel); 2017 Apr; 9(5):. PubMed ID: 28448462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATR/CHK1 inhibitors and cancer therapy.
    Qiu Z; Oleinick NL; Zhang J
    Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple-Negative Breast Cancer and Emerging Therapeutic Strategies: ATR and CHK1/2 as Promising Targets.
    Sofianidi A; Dumbrava EE; Syrigos KN; Nasrazadani A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
    Edwards TG; Bloom DC; Fisher C
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy.
    Manic G; Obrist F; Sistigu A; Vitale I
    Mol Cell Oncol; 2015; 2(4):e1012976. PubMed ID: 27308506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress towards a clinically-successful ATR inhibitor for cancer therapy.
    Barnieh FM; Loadman PM; Falconer RA
    Curr Res Pharmacol Drug Discov; 2021; 2():100017. PubMed ID: 34909652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New horizons in lung cancer management through ATR/CHK1 pathway modulation.
    Thapa R; Afzal O; Bhat AA; Goyal A; Alfawaz Altamimi AS; Almalki WH; Alzarea SI; Kazmi I; Singh SK; Dua K; Thangavelu L; Gupta G
    Future Med Chem; 2023 Oct; 15(19):1807-1818. PubMed ID: 37877252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
    Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
    J Virol; 2019 May; 93(9):. PubMed ID: 30787154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells.
    Takeuchi M; Tanikawa M; Nagasaka K; Oda K; Kawata Y; Oki S; Agapiti C; Sone K; Miyagawa Y; Hiraike H; Wada-Hiraike O; Kuramoto H; Ayabe T; Osuga Y; Fujii T
    Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31805725
    [No Abstract]   [Full Text] [Related]  

  • 11. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
    Boudny M; Trbusek M
    Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting ATR in cancer medicine.
    Sundar R; Brown J; Ingles Russo A; Yap TA
    Curr Probl Cancer; 2017; 41(4):302-315. PubMed ID: 28662958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Thieno[3,2-d]pyrimidine derivatives as potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) kinase.
    Duan Y; Cheng H; Zhuang L; Xia J; Xu Y; Zhang R; Sun R; Lu T; Chen Y
    Eur J Med Chem; 2023 Jul; 255():115370. PubMed ID: 37130473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
    Ngoi NYL; Peng G; Yap TA
    Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of Ataxia Telangiectasia and Rad3 related kinase (ATR) sensitize lymphoma cells to UVA radiation.
    Biskup E; Naym DG; Gniadecki R
    J Dermatol Sci; 2016 Dec; 84(3):239-247. PubMed ID: 27743911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand.
    Mei L; Zhang J; He K; Zhang J
    J Hematol Oncol; 2019 Apr; 12(1):43. PubMed ID: 31018854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
    Smith J; Tho LM; Xu N; Gillespie DA
    Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
    Bradbury A; Hall S; Curtin N; Drew Y
    Pharmacol Ther; 2020 Mar; 207():107450. PubMed ID: 31836456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
    Shaik A; Bhakuni R; Kirubakaran S
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
    Massey AJ
    Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.